What is the significance of the FDA approval for ARCALYST®?

The FDA approval for ARCALYST® marks Regeneron's first commercial drug product, representing a major transition from a pure R&D company to one with a commercial offering. This approval is a critical step towards generating product sales revenue and validating the company's drug development capabilities.

How is Regeneron funding its significant R&D expenses?

Regeneron is primarily funding its substantial research and development expenses through revenue generated from its strategic collaborations with major pharmaceutical companies, notably sanofi-aventis and Bayer HealthCare. These agreements provide upfront payments, milestone payments, and cost reimbursements that support the company's innovation pipeline.

What is the company's current financial position in terms of cash and debt?

As of December 31, 2008, Regeneron had $247.8 million in cash and cash equivalents. The company repaid its $117.5 million in convertible senior subordinated notes upon their maturity in October 2008, reducing its long-term debt obligations. The decrease in cash from the previous year is largely attributed to R&D investments and capital expenditures.

What is the company's outlook for profitability given the net loss in 2008?

Regeneron has historically incurred net losses due to significant investments in research and development. The company's strategy relies on advancing its pipeline and leveraging collaborations to fund operations. Future profitability will depend on the successful commercialization of ARCALYST, the progression of its pipeline candidates through clinical trials and regulatory approvals, and the continued success of its strategic partnerships.

REGN 10-K FY2008 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its 2008 fiscal year results, highlighting significant progress in its drug development pipeline and strategic collaborations. The company received FDA approval for its first commercial drug, ARCALYST® (rilonacept) Injection for Subcutaneous Use, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). This marks a crucial milestone, transitioning Regeneron towards becoming a commercial-stage biopharmaceutical company. Financially, Regeneron continued to invest heavily in research and development, which contributed to an operating loss for the year. However, revenue streams from key collaborations, particularly with sanofi-aventis and Bayer HealthCare, provided substantial funding for these R&D efforts. The company's cash position decreased year-over-year, primarily due to significant R&D spending and capital expenditures, alongside the repayment of convertible notes. Investors should monitor the progression of ARCALYST sales and the continued success of its strategic partnerships for future growth.

Key Highlights

1Received FDA marketing approval for ARCALYST® (rilonacept) Injection for Subcutaneous Use, the company's first commercial drug product.
2Generated significant contract research and development revenue, primarily from collaborations with sanofi-aventis ($153.97 million) and Bayer HealthCare ($31.2 million).
3Invested heavily in research and development, with R&D expenses totaling $278.02 million, an increase from the prior year, reflecting continued pipeline investment.
4Experienced a net loss of $82.71 million for the year ended December 31, 2008.
5Ended the year with $247.8 million in cash and cash equivalents, a decrease from $498.9 million at the end of 2007, partly due to debt repayment.
6The company repaid its entire $117.5 million of outstanding convertible senior subordinated notes upon maturity in October 2008.

Revenue	$238.46M
Cost of Revenue	$923K
Gross Profit	$237.53M
R&D Expenses	$274.90M
SG&A Expenses	$48.88M
Operating Expenses	$324.71M
Operating Income	-$86.25M
Interest Expense	$7.75M
Net Income	-$79.13M

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2008

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions